<code id='18A2D108C1'></code><style id='18A2D108C1'></style>
    • <acronym id='18A2D108C1'></acronym>
      <center id='18A2D108C1'><center id='18A2D108C1'><tfoot id='18A2D108C1'></tfoot></center><abbr id='18A2D108C1'><dir id='18A2D108C1'><tfoot id='18A2D108C1'></tfoot><noframes id='18A2D108C1'>

    • <optgroup id='18A2D108C1'><strike id='18A2D108C1'><sup id='18A2D108C1'></sup></strike><code id='18A2D108C1'></code></optgroup>
        1. <b id='18A2D108C1'><label id='18A2D108C1'><select id='18A2D108C1'><dt id='18A2D108C1'><span id='18A2D108C1'></span></dt></select></label></b><u id='18A2D108C1'></u>
          <i id='18A2D108C1'><strike id='18A2D108C1'><tt id='18A2D108C1'><pre id='18A2D108C1'></pre></tt></strike></i>

          
          WSS
          Rachel Haurwitz of Caribou Biosciences
          Rachel Haurwitz, CEO of Caribou Biosciences. Elizabeth D. Herman for STAT

          Caribou Biosciences said Thursday that its off-the-shelf CAR-T therapy induced durable, complete remissions in patients with advanced B-cell lymphoma that move it closer to the benchmarks set by more established, patient-specific CAR-T therapies.

          In an update to an early-stage study, 44% of the 16 patients treated with Caribou’s on-demand therapy, called CB-010, achieved a complete remission lasting a minimum of six months — a key threshold of durability.

          advertisement

          The CB-010 result is still preliminary, but it begins to compare favorably to currently approved CAR-T therapies, which must be custom made for each patient and have shown durable remission rates in the range of 36-40%, said Caribou CEO Rachel Haurwitz.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          hotspot